Editorial: Commercialization and industrialization of pharmacology of infectious diseases: 2022

Yanqin Huang; Sue C Nang; Yu-Wei Lin; Fekade Sime

doi:10.3389/fphar.2024.1438072

Editorial: Commercialization and industrialization of pharmacology of infectious diseases: 2022

Front Pharmacol. 2024 Jun 19:15:1438072. doi: 10.3389/fphar.2024.1438072. eCollection 2024.

Authors

Yanqin Huang^{1

2}, Sue C Nang³, Yu-Wei Lin^{3

4

5

6

7}, Fekade Sime⁸

Affiliations

¹ Department of Pathology, Beth Israel Deaconess Medical Center, Boston, MA, United States.
² Harvard Medical School, Boston, MA, United States.
³ Department of Microbiology, Biomedicine Discovery Institute, Monash University, Melbourne, VIC, Australia.
⁴ Monash Institute of Pharmaceutical Sciences, Monash University, Melbourne, VIC, Australia.
⁵ Malaya Translational and Clinical Pharmacometrics Group, Faculty of Pharmacy, Universiti Malaya, Kuala Lumpur, Malaysia.
⁶ Department of Pharmacy and Pharmacy Practice, Faculty of Pharmacy, Universiti Malaya, Kuala Lumpur, Malaysia.
⁷ Certara Drug Development Solutions, Certara, Radnor, PA, United States.
⁸ Centre for Clinical Research, The University of Queensland, Brisbane, QLD, Australia.

No abstract available

Keywords: augmented renal clearance; cefoperazone/sulbactam; etimicin; hollow fiber infection model; lefamulin; personalized antibiotic dosing; population pharmacokinetic (PPK); teicoplanin.

Publication types

Editorial

Grants and funding

The author(s) declare that no financial support was received for the research, authorship, and/or publication of this article.